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Defective phagocytosis has been shown in chronic obstructive pulmonary disease 
(COPD) bronchoalveolar lavage and blood monocyte- derived macrophages. Phagocytic 
capabilities of sputum macrophages and neutrophils in COPD are unknown. We inves-
tigated phagocytosis in these cells from COPD patients and controls. Phagocytosis of 
Streptococcus pneumoniae or fluorescently labelled non- typeable Haemophilus influ-
enzae (NTHi) by sputum macrophages and neutrophils was determined by gentamycin 
protection assay (COPD; n = 5) or flow cytometry in 14 COPD patients, eight healthy 
smokers (HS) and nine healthy never- smokers (HNS). Sputum macrophages and neutro-
phils were differentiated by adherence for the gentamycin protection assay or receptor 
expression (CD206 and CD66b, respectively), by flow cytometry. The effects of NTHi 
on macrophage expression of CD206 and CD14 and neutrophil expression of CD16 were 
determined by flow cytometry. There was greater uptake of S. pneumoniae [~10- fold 
more colony- forming units (CFU)/ml] by sputum neutrophils compared to macrophages 
in COPD patients. Flow cytometry showed greater NTHi uptake by neutrophils com-
pared to macrophages in COPD (67 versus 38%, respectively) and HS (61 versus 31%, 
respectively). NTHi uptake by macrophages was lower in HS (31%, p  =  0.019) and 
COPD patients (38%, p = 0.069) compared to HNS (57%). NTHi uptake by neutrophils 
was similar between groups. NTHi exposure reduced CD206 and CD14 expression on 
macrophages and CD16 expression on neutrophils. Sputum neutrophils showed more 
phagocytic activity than macrophages. There was some evidence that bacterial phago-
cytosis was impaired in HS sputum macrophages, but no impairment of neutrophils was 
observed in HS or COPD patients. These results highlight the relative contributions of 
neutrophils and macrophages to bacterial clearance in COPD.
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INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is char-
acterized by airflow obstruction and excessive pulmonary 
inflammation in response to the inhalation of noxious par-
ticles, such as cigarette smoke. COPD lungs have increased 
numbers of macrophages and neutrophils, as these cells act 
to clear harmful particles in the airways (1). However, these 
innate immune cells also cause an increased inflammatory 
burden in the lungs of COPD patients (1).
The airways of COPD patients may become colonized with 
bacteria, commonly Haemophilus influenzae, Streptococcus 
pneumoniae and Moraxella catarrhalis. The presence of these 
bacteria in the airways is associated with exacerbations (2– 
4). Furthermore, bacterial colonization is associated with in-
creased airway inflammation in COPD patients (4– 8). Sputum 
samples represent the upper airway environment, and there is 
increasing evidence of the importance of the sputum micro-
biome in COPD, as reduced sputum microbiome diversity is 
associated with more frequent exacerbations (4,8,9).
Macrophages and neutrophils are professional phagocytes 
that ingest bacteria (10). Alveolar macrophages and blood 
monocyte- derived macrophages (MDMs) differentiated by 
culture with granulocyte– macrophage colony- stimulating 
factor (GM- CSF) have been used to show that macrophage 
phagocytosis, including both H. influenzae and S. pneumo-
niae, is defective in COPD patients (11– 14). Subpopulations 
of pulmonary macrophages exist with differences in phe-
notype, marker expression (15) and function (16). Alveolar 
macrophage subpopulations based on size and expression 
levels of surface markers CD206 and CD14 show differ-
ences in phagocytic capabilities towards bacteria: large, 
CD206highCD14low alveolar macrophages have lower phago-
cytic capabilities compared to small CD206lowCD14high al-
veolar macrophages (16). Sputum phagocytes from healthy 
individuals are functionally more active than phagocytes 
from alveolar airways and blood, suggesting that the upper 
airways are an important site for microbial clearance (17). 
However, defects in bacterial phagocytosis have not been 
studied in COPD sputum cells. It should be noted that the 
absolute number of sputum neutrophils and macrophages are 
increased in COPD patients compared to healthy controls, 
with a relative increase in neutrophil percentage in COPD 
patients. This suggests that sputum neutrophils have an im-
portant role in upper airway phagocytosis in COPD patients.
There are conflicting data on neutrophil phagocytosis in 
COPD, with some studies showing a reduction (18) and oth-
ers no difference compared to controls (19). However, these 
studies have used blood neutrophils or non- disease- relevant 
pathogens. It remains unclear if the phagocytic capabilities 
of lung neutrophils are impaired in COPD.
The aim of this study was to simultaneously assess the 
phagocytosis ability of both sputum macrophages and 
neutrophils in COPD and controls. We also studied the ef-




Sputum samples were collected from eight healthy never 
smoker (HNS) controls, eight healthy smoker (HS) controls 
and 14 COPD patients; demographics are shown in Table 1. 
COPD was diagnosed based on ≥  10 pack- years smoking 
history and GOLD criteria (20). HS had no airflow limita-
tion. Sample collection was approved by the local research 
ethics committee (NRES Committee North West– Greater 
Manchester South; REC Ref: 06/Q1402/41). All subjects 
provided written informed consent.
Sputum processing
Sputum samples were processed to obtain cell pellets for im-
mune cell counting and culture as previously described (21). 
Sputum macrophages and neutrophils were isolated by plat-
ing sputum cells in 48- well plates at 0.1 × 106 macrophages 
per well and leaving to adhere for 2 h. Non- adherent cells 
were removed, counted and plated at 0.1  ×  106 cells per 
well to ensure comparable cell numbers. Cells were cultured 
overnight in antibiotic free Iscove’s modified Dulbecco’s 
medium (IMDM) with 10% human serum. Adherent cell 
population were confirmed by differential cell counts, as 92% 
macrophages and non- adherent population were 83% neutro-
phils (Supporting information, Figure S1, Table S1)
Phagocytosis of S. pneumoniae
S. pneumoniae (ATCC: 700902) was added at a multiplicity 
of infection of 10:1 in phosphate- buffered saline (PBS) or 
PBS alone for unstimulated controls for 3 h. Living internal-
ized S. pneumoniae was assessed using gentamycin protec-
tion assay described online.
Phagocytosis of H. influenzae: flow cytometry
Cells were exposed to pHrodo- labelled heat- killed non- 
typeable H. influenzae (ATCC 53600) (pHrodo NTHi) 
(generated by GSK) for 30  min and 3  h prior to stain-
ing with anti- CD45, anti- CD66b (gating neutrophils), 
anti- CD206 (gating macrophages), anti- CD16 and anti-
 CD14 (details online). Cells were gated for phagocytosis 
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(Supporting information, Figure S2) and for subpopula-
tion analysis (Supporting information, Figure S3) using 
fluorescence minus one (FMO) controls to give a cut- off of 
either positive or negative for each marker expression (de-
scribed online). Culture with pHrodo had no effect on cell 
viability (Supporting information, Figure S4). The percent-
age of positive and median fluorescence intensity (MFI) 
of stained populations were measured. The percentage 
positive of pHrodo indicates the percentage of the given 
cell populations that have phagocytosed the pHrodo NTHi. 
The MFI represents the average fluorescence intensity of 
the given cell populations, intensity per cell. The distri-
bution of fluorescence for pHrodo is a bimodal distribu-
tion. and therefore MFI is not an accurate representation 
for this assay. MFI data are not presented for phagocytosis. 
The percentage of positive and MFI are shown for surface 
marker expression data.
Statistical analysis
Normality of data was assessed using the Shapiro– Wilk 
normality test. Gentamycin protection assay data were 
non- parametric. Comparisons between conditions were 
assessed by Friedman’s test and between time- points by 
Wilcoxon’s test. Flow cytometry data were normally dis-
tributed. Comparisons between conditions were assessed 
by analysis of variance (ANOVA) with Tukey’s multiple 
comparisons test. Comparisons between time- points were 
by paired t- test. Comparisons between unexposed and ex-
posed conditions were assessed by unpaired t- test, between 
time- points were by paired t- test and between groups were 
by ordinary one- way ANOVA with Tukey’s multiple com-
parisons test. Subanalysis comparisons between COPD cur-
rent smokers and COPD ex- smokers were performed using 
paired t- tests. All analysis was carried out using GraphPad 




Subject demographics are shown in Table 1; the mean post- 
bronchodilator forced expiratory volume in 1 second (FEV1) 
T A B L E  1  Patient demographics
HNS HS COPD
Male/female, n 5/4 3/5 14/0
Age (years) 54 (34– 67) 56 (29– 76) 71 (59– 80)**#
Current/ex- smoker, n 0/0 8/0 5/9
Pack- years n/a 22 (11– 58) 60 (25– 83.75###
Exacerbations in last year n/a 0.25 ± 0.7 1 ± 1.3
ICS (yes/no), n 0/9 0/8 12/2
SABA 0/9 0/8 13/1
LABA 0/9 0/8 12/2
LAMA 0/9 0/8 12/2
FEV1 (l) 3.1 ± 0.6 2.8 ± 1.2 1.6 ± 0.6
**#
FEV1 (%) 101.9 ± 11.3 99.9 ± 13.9 56.3 ± 21.4
***###
FVC (l) 4.1 ± 0.9 3.7 ± 1.4 3.3 ± 0.6
FEV1/FVC ratio (%) 75.4 ± 3.6 74.2 ± 6.4 46.7 ± 16.7
***###
Reversibility (%) 0.6 ± 2.7 3.6 ± 6.3 11.4 ± 13.9
Sputum neutrophil (%) 52.3 ± 25.9 54.1 ± 17.2 76.0 ± 20.1*#
Sputum neutrophil cell count ×106/g 3.9 ± 3.9 3.3 ± 1.9 11.0 ± 11.0
Sputum macrophage (%) 29.6 ± 17.3 38.9 ± 12.4 16.7 ± 14.8#
Sputum macrophage cell count ×106/g 1.6 ± 1.1 1.9 ± 0.8 1.2 ± 0.5
Sputum eosinophils (%) 0.4 ± 0.4 0.9 ± 1.0 2.4 ± 3.5
Sputum eosinophils cell count ×106/g 0.0003 ± 0.0007 0.0001 ± 0.0004 0.0005 ± 0.001
Data are presented as mean ± standard deviation or median (range).
Forced expiratory volume in one second (FEV1)% of predicted maximum, forced vital capacity (FEVC), inhaled corticosteroids (ICS), long acting β- agonists (LABA), 
long- acting muscarinic antagonists (LAMA), short- acting β- agonists (SABA), reversibility % of FEV1 improvement following bronchodilator treatment.
Significant compared to HNS (*p < 0.05, **0.01, ***0.001); significant compared to HS (#p < 0.05, ##0.01, ###0.001).
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in COPD patients was 48.6%, with no exacerbations in the 
previous year in 54.5% of patients. Some HS also reported 
previous exacerbations. The median age of the COPD group 
was significantly higher compared to both control groups 
(p < 0.05). The percentage of sputum neutrophils was sig-
nificantly higher and macrophages lower in the COPD group 
(p < 0.05).
Phagocytosis of S. pneumoniae
Macrophages and neutrophils were separated by adherence 
from COPD sputum samples (n  =  5). Internalization of S. 
pneumoniae by both cell populations was determined using 
the gentamycin protection assay. Both macrophages and neu-
trophils exposed to S. pneumoniae for 3 h showed significant 
(p < 0.01) uptake of bacteria (Supporting information, Figure 
5a,b, respectively). A significantly greater number of inter-
nalized bacteria were present in exposed neutrophils com-
pared to macrophages (p < 0.01) (Figure 1).
Phagocytosis of NTHi
Sputum cells from 14 COPD patients, eight HS and nine HNS 
(Table 1) were exposed to pHrodo labelled NTHi for 30 min 
and 3 h or left unexposed. The percentage of NTHi- positive 
CD206+ and CD66b+ cells was determined by flow cytom-
etry, measuring bacterial internalisation in macrophages and 
neutrophils, respectively.
NTHi internalization was observed in both CD206+ 
and CD66b+ cell populations (Figure 2a). The percentage 
of CD206+ and CD66b+ cells positive for NTHi was sig-
nificantly increased at both 30  min and 3  h in all groups 
(p  <  0.01 all comparisons; Supporting information, Figure 
S6, showing exposed versus unexposed cells). NTHi phago-
cytosis was numerically increased in CD206+ and CD66b+ 
cells at 3  h compared to 30  min (Supporting information, 
Figure S7), reaching significance for some conditions (full 
analysis online).
The percentage of phagocytosing CD66b+ cells was 
higher than CD206+ cells, reaching statistical significance 
for HS and COPD patients at 30 min and 3 h (all p < 0.05; 
Figure 2b,c).
The percentage of phagocytosing CD206+ cells was lower 
in HS and COPD compared to HNS, with this difference 
reaching statistical significance for HS at 3  h (p = 0.019), 
while significance was not achieved (p = 0.069) for COPD 
patients (Figure 2c). There were no differences in the per-
centage of NTHi in CD66b+ cells between groups at either 
time- point.
Subanalysis of the COPD group showed no differences 
between current (n = 5) and ex- smokers (n = 9) for either 
CD206+ or CD66b+ cells at 30 min (p = 0.22 and p = 0.26, 
respectively) or 3 h (p = 0.83 and p = 0.27, respectively).
Cell surface markers after NTHi exposure
Macrophage expression of CD206 and CD14
The expression of CD206 and CD14 on CD66b− cells was 
determined by flow cytometry (gating strategy, Supporting 
information, Figure S3a) to give four subpopulations; 
CD206+CD14high, CD206+CD14low, CD206- CD14high and 
CD206- CD14low.
Following exposure to pHrodo NTHi, the percentage 
of CD206+CD14high cells were decreased in all groups and 
CD206+CD14low cells in HNS after 3 h (Figure 3a,b, respec-
tively). Conversely, the percentage of CD206−CD14low cells 
was increased in all groups after 3 h (Figure 3d). There were 
no differences in the percentage of CD206−CD14high cells 
(Figure 3c). Exposure for 30 min and 3 h were generally sim-
ilar (Supporting information, Figure S8).
All cell populations showed significant uptake of 
NTHi compared to unexposed cells (Figure 4). There 
were no differences between groups for phagocytosis for 
CD206+ cells; however, the percentage of phagocytosing 
F I G U R E  1  Phagocytosis of Streptococcus pneumoniae in sputum 
cells. Sputum cells from five chronic obstructive pulmonary disease 
(COPD patients were separated into macrophages and neutrophils by 
adherence and left unexposed or exposed to Streptococcus pneumoniae 
for 3 h. Internalization of bacteria was then determined by gentamycin 
protection assay. Phagocytic capability of macrophages and 
neutrophils from the same sputum sample were compared. Data are 
presented as individual donors with median. Non- parametric analysis 
of variance (ANOVA) (Friedman’s test) followed by Dunn’s multiple 
comparisons were used to compare cell types. Significantly above 
macrophages (**p < 0.01)
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CD206−CD14high cells was significantly lower at 3  h in 
COPD patients compared to HNS (p  <  0.05) (Figure 4). 
Subanalysis of the COPD group showed no differences 
between current (n = 5) and ex- smokers (n = 9) at either 
30 min or 3 h for CD206+CD14high (p = 0.07 and p = 0.83, 
respectively), CD206+CD14low (p = 0.42 and p = 0.35, re-
spectively), CD206−CD14high (p  =  0.11 and p  =  0.63 re-
spectively) and CD206−CD14low (p = 0.99 and p = 0.26, 
respectively).
Neutrophil expression of CD16
The MFI of basal CD16 expression on unexposed CD66b+ 
cells was determined by flow cytometry (Figure 5a). Basal 
CD16 expression was significantly reduced at 3  h culture 
compared to 30  min; MFI in HNS and COPD (p  <  0.05 
and p  =  0.01, respectively); and the percentage of CD16- 
positive cells in HS and COPD (p < 0.05 both comparisons; 
Supporting information, Figure S9). There were no differ-
ences between groups in basal expression of CD16 (percent-
age or MFI) at either 30 min or 3 h of culture (Supporting 
information, Figure S10).
NTHi exposure reduced CD16 expression compared to 
baseline in CD66b+ cells; MFI was significantly reduced in 
all groups at 3  h (p  <  0.05) and the percentage of CD16- 
positive cells was significantly reduced compared to baseline 
in HS and COPD at both time- points (p < 0.05; Figure 5).
Both CD16+ and CD16− cells showed significant uptake 
of NTHi in all groups at both time- points (Supporting in-
formation, Figure S11). The percentage of phagocytosing 
CD66b+CD16− cells was lower in COPD cells compared to 
F I G U R E  2  Phagocytosis of pHrodo non- typeable Haemophilus influenzae (NTHi) in CD66b+ and CD206+ sputum cells. Sputum cells 
from 14 chronic obstructive pulmonary disease (COPD) patients, eight healthy smokers (HS) and nine healthy never- smokers (HNS) were either 
unexposed or exposed with pHrodo NTHi bacteria for 30 min or 3 h. Cells were then harvested and stained with CD45, CD66b and CD206 and 
the data acquired using the BD Canto II flow cytometer. CD45+CD206+ and CD45+CD66b+ cells were gated and the percentage of NTHi- positive 
cells (a) was analysed after 30 min (b) and 3 h (c) by FlowJo. Data are representative from healthy never- smokers (HNS) (a) and presented 
as mean ± standard error of the mean (SEM) (b,c). Statistical significance is shown above corresponding bars [ordinary analysis of variance 
(ANOVA) followed by Tukey’s multiple comparison test between groups for each cell type, paired t- tests between cell types within each group]. 
Significance between CD206+ and CD66b+ cells (*p < 0.05, **p < 0.01 and ***p < 0.001, respectively). Significance between groups for CD206+ 
cells (#p < 0.05)
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HNS at 30 min (p < 0.05), while there were no differences 
between groups for CD66b+CD16+ cells (Supporting informa-
tion, Figure S11). Subanalysis of the COPD group showed no 
differences between current (n = 5) and ex- smokers (n = 9) at 
either 30 min or 3 h for CD16+ (p = 0.16 and p = 0.66, respec-
tively), or CD16− cells (p = 0.21 and p = 0.24, respectively).
DISCUSSION
We observed greater phagocytosis of both S. pneumoniae 
and NTHi (assessed by gentamycin protection and flow cy-
tometry, respectively) by sputum neutrophils compared to 
macrophages from the same sample. This finding was most 
clearly observed in HS and COPD patients, indicating that 
neutrophils are an important phagocytic cell in the upper air-
ways in these subject groups. While neutrophil phagocytosis 
is often studied using peripheral blood cells, our results using 
sputum cells indicate no loss of phagocytic ability in COPD 
neutrophils compared to controls. It is known that COPD al-
veolar macrophages have defective phagocytosis compared 
to controls. We found some evidence that COPD and HS 
sputum macrophage phagocytosis was reduced compared to 
HNS, although statistical significance was not reached for 
COPD patients.
The relative contribution of neutrophils and macrophages 
to airway phagocytosis has not previously been studied in 
parallel. The data presented here suggest that sputum neu-
trophils are more effective phagocytes than sputum macro-
phages, with a greater capacity and more rapid phagocytosis. 
It has been shown that blood neutrophils from COPD patients 
have defective phagocytosis compared to controls (18), al-
though others have observed no differences between these 
groups (19). This study is the first to assess sputum neutro-
phil phagocytosis in COPD and shows no differences be-
tween groups in the uptake of NTHi.
F I G U R E  3  The effects of pHrodo non- typeable Haemophilus influenzae (NTHi) exposure on CD206+/− CD14high/low expression by sputum 
cells. Sputum cells from 14 chronic obstructive pulmonary disease (COPD) patients, eight healthy smokers (HS) and nine healthy never- smokers 
(HNS) were either unexposed or exposed with pHrodo NTHi bacteria for 3 h. Cells were then harvested and stained with CD45, CD66b, CD206 
and CD14 and the data acquired using the BD Canto II flow cytometer. CD45+CD66b− cells were gated and the percentage of CD206+CD14high 
(a), CD206+CD14low (b), CD206−CD14high (c) and CD206−CD14low (d) populations analysed by FlowJo. Data are presented as mean ± standard 
error of the mean (SEM). Statistical significance is shown above corresponding bars (t- test). Significance between unexposed and NTHi exposed 
(*p < 0.05, **p < 0.01 and ***p < 0.001, respectively)
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We also conducted experiments to investigate changes 
in cell activation and phenotype caused by phagocytosis. 
Sputum macrophage expression of CD206 and CD14 and 
sputum neutrophil expression of CD16 were all reduced after 
exposure to NTHi. These findings agree with studies show-
ing altered macrophage cell surface markers after bacterial 
exposure (22), indicating that bacterial exposure can skew 
innate immune function.
Numerically greater phagocytosis in neutrophils com-
pared to macrophages was observed among all groups, but 
was not statistically significant in HNS for NTHi phagocyto-
sis. Sputum neutrophil numbers are increased in smokers and 
COPD patients (1), and we now show that these cells have 
a greater phagocytic capability than sputum macrophages. 
Defects in macrophage phagocytosis linked to smoking and/
or the development of COPD may result in neutrophils ac-
quiring a more important role in upper airway bacterial clear-
ance. The potential role of macrophages in the clearance of 
apoptotic neutrophils (23) and thus secondary clearance of 
bacteria was not studied here, and may be important.
We show a decrease in phagocytosis for both COPD pa-
tients and HS in the uptake of NTHi bacteria by sputum mac-
rophages compared to HNS. These results support reduced 
bacterial phagocytosis by COPD macrophages shown in 
bronchial lavage macrophages (13,24) and MDMs when dif-
ferentiated by culture with GM- CSF (12). While there was a 
numerical reduction of phagocytosis in COPD macrophages 
compared to healthy controls, the lack of statistical signif-
icance contrasts with those studies using alveolar macro-
phages (13,24), highlighting potential functional differences 
between sputum and alveolar macrophages. There are con-
flicting data for macrophage phagocytosis in HS with reports 
of a reduction (25) and no difference (12), with phagocytosis 
in COPD patients being independent of smoking status (24). 
Cigarette smoke exposure in vitro directly reduces macro-
phage phagocytosis of NTHi (25), implicating smoking as the 
cause of the defect that we observed in sputum macrophages.
Smokers without airflow obstruction can have increased 
respiratory symptoms and exacerbation frequency (26). 
Previous exacerbations were reported by some HS in the 
current study. While self- reporting of exacerbations without 
clear definitions can be unreliable, impaired Toll- like recep-
tor responses of alveolar macrophages have been shown in 
exacerbation- prone COPD patients using more exact defi-
nitions of exacerbations (27). Overall, reduced phagocyto-
sis and bacterial clearance by sputum macrophages in HS 
may contribute to bacterial colonization, predisposing to in-
creased symptoms and exacerbations, and perhaps increasing 
the risk of developing COPD (28).
We previously identified pulmonary macrophage sub-
populations based on size and location with differences in 
marker expression and phagocytic capabilities. Small alve-
olar macrophages, identified as CD206lowCD14high, have 
a greater phagocytic capability compared to large alveolar 
macrophages, CD206highCD14low (16). Similar subpopula-
tions exist in sputum (29). In COPD the expression of CD206 
is further decreased on small alveolar macrophages isolated 
from both lung resection and sputum (16,30). As CD206, the 
mannose receptor, is involved in bacterial recognition, lower 
expression of this marker may contribute to reduced phago-
cytic capabilities of this subpopulation. We show a decrease 
in CD206 and CD14 expression on sputum macrophages 
after NTHi exposure consistent with lung resection macro-
phage data, which also shows an increase in tumour necrosis 
factor (TNF)- α and CD38 (22) associated with an inflamma-
tory macrophage phenotype. Also, NTHi colonization of the 
F I G U R E  4  Phagocytosis of pHrodo non- typeable Haemophilus influenzae (NTHi) in CD206+/− CD14high/low sputum cells. Sputum cells from 
14 chronic obstructive pulmonary disease (COPD) patients, eight healthy smokers (HS) and nine healthy never- smokers (HNS) were left unexposed 
or exposed to pHrodo NTHi for 30 min or 3 h. The percentage of phagocytosing cells was then determined by flow cytometry. CD66b− cells were 
gated and CD206+CD14low, CD206+CD14high, CD206−CD14high and CD206−CD14low populations were further analysed to reveal the percentage 
(a,b) of phagocytosing cells in each population. Data are presented as mean ± standard error of the mean (SEM). Statistical significance is shown 
above corresponding bars [analysis of variance (ANOVA) followed Tukey’s multiple comparison test]. Significantly below HNS (*p < 0.05)
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airways is associated with increased levels of other proin-
flammatory signalling pathways in sputum (4,31). However, 
while both CD206 and CD14 expression on lung tissue mac-
rophages is lower in COPD compared to smoking and non- 
smoking controls (32), we showed no differences between 
groups for sputum macrophages. Also we showed no differ-
ences between current and ex- smoking patients for any anal-
ysis, although the sample sizes (five and nine) were limited 
and further investigation would be of potential interest.
Neutrophils express cell surface Fc- gamma receptors 
CD16 (FcyRIII) and CD32 (FcyRII) for recognition of im-
munoglobulin (Ig) opsonized bacteria. CD64, the high- 
affinity Fc- gamma receptor, is also expressed on neutrophils, 
but only when primed (33). We showed in all groups that 
NTHi exposure reduced CD16 levels. CD16 expression is a 
surface biomarker for tracking neutrophil apoptosis and func-
tion, with apoptotic neutrophils expressing 90% less CD16 
(34). Exposure to NTHi and/or phagocytosis may induce 
F I G U R E  5  The effects of pHrodo non- typeable Haemophilus influenzae (NTHi) exposure on CD16 expression by sputum neutrophils. Sputum 
cells from 14 chronic obstructive pulmonary disease (COPD) patients, eight healthy smokers (HS) and nine healthy never- smokers (HNS) were 
either unexposed or exposed with pHrodo NTHi bacteria for 30 min and 3 h. Cells were then harvested and stained with CD45, CD66b and CD16 
and the data acquired using the BD Canto II flow cytometer. CD45+CD66b+ cells were gated (a) and the percentage (b,c) and mean fluorescence 
intensity (MFI) (d,e) of CD16 analysed by FlowJo. Data are presented as mean ± standard error of the mean (SEM). Statistical significance 
is shown above corresponding bars (t- test). Significance between unexposed and NTHi exposed (*p < 0.05, **p < 0.01 and ***p < 0.001, 
respectively)
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apoptosis, thereby reducing CD16 expression (34). CD16 
reduction was only observed in non- smokers after 3 h expo-
sure compared to 30 min in smokers and COPD, suggesting 
that smokers and COPD sputum neutrophils respond more 
quickly to NTHi.
As flow cytometry analysis only detects surface expres-
sion of CD16, the reduction observed may be due to internal-
ization of the receptor upon bacterial exposure (35). CD16 
was also reduced in culture over time, a decrease which was 
significant in COPD and HS. Blood neutrophils have a short 
half- life and undergo apoptosis after approximately 20 h of 
culture (36). It is possible that during the culture period neu-
trophils become more apoptotic, resulting in decreased CD16, 
with this process occurring more readily in cells from HS and 
COPD patients. However, peripheral blood neutrophils from 
COPD patients show no difference in spontaneous apoptosis 
compared to HS (37) and delayed apoptosis induced by fMLP 
(38) or during exacerbation (39).
Limitations
A study limitation was that insufficient sputum quantity 
was obtained from control subjects to assess S. pneumoniae 
phagocytosis and the sample size for this experiment was 
relatively small. Also, the COPD group recruited was sta-
tistically older compared to the controls, and male and age 
and gender could not be entirely discounted as independent 
variables.
Another limitation was that the identification of poten-
tially pathogenic bacteria in the sputum samples was not 
available for the patients utilized in the study. The increased 
presence of pathogenic bacteria is inversely associated with 
defective bacterial phagocytosis of MDMs (40), and it would 
be of interest to investigate if similar differences are observed 
in neutrophils.
As pHrodo labelling relies upon acidification to detect 
phagocytosis, it is possible that internalization of bacteria 
may be undetected if it subverted endosomal acidification. 
However, it has been shown that alveolar macrophages in-
gest and eliminate NTHi by phagolysomal fusion and do 
not subvert endosomal acidification to any great degree 
(25). The gentamicin protection assay represents a snap-
shot in time of live bacteria contained within in the cells 
and thus altered numbers of live bacteria may be due to an 
increase in killing, as opposed to reduced phagocytosis. 
However, the flow cytometry assay (used at both 30 min 
and 3 h) does not utilize live bacteria, and therefore is not 
influenced by bacterial killing. Also, the time- point of 3 h 
of culture with the bacteria is relatively short compared to 
other studies which utilized this method to assess macro-
phage phagocytosis and killing of S. pneumoniae where 
optimal killing is assessed at 6– 16  h (41,42). While the 
ex- vivo culture of the sputum cells may have altered their 
phenotype (decreased CD16 expression on neutrophils 
observed over time), consistent observations of higher 
phagocytosis in neutrophils compared to macrophages 
were shown at 30 min, 3 h (flow analysis) and overnight 
(gentamycin protection) culture.
Differences between COPD and control macrophages 
have been observed in uptake of both opsonized and non- 
opsonized S. pneumoniae and NTHi (40). Opsonization has 
been shown to increase the uptake and killing of S. pneu-
moniae by human alveolar macrophages (43). In the present 
study, both methods of phagocytosis investigated the uptake 
of opsonized bacteria; also, the bacterial species S. pneumo-
niae and NTHi are both heterogeneous, and results with other 
strains may vary from our findings.
We simultaneously assessed the phagocytic capabilities of 
both sputum macrophages and sputum neutrophils in COPD 
patients and controls. We show that the phagocytic capabil-
ities of sputum neutrophils, which are greater than those of 
sputum macrophages, is unaltered in COPD. We also show 
smoking reduces sputum macrophage phagocytosis capabil-
ity. The dynamic between neutrophil and macrophage phago-
cytosis is altered in HS and COPD patients, potentially due to 
macrophage defects. The data presented show that sputum is 
an ideal sample type for studying phagocytosis in the upper 
airways, and highlights the importance of investigating the 
interplay between neutrophils and macrophages in bacterial 
clearance in COPD.
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